Genmab shares rise 4% on J&J cancer drug FDA approval
Summary
Genmab saw its stock price increase by four percent following the regulatory approval of a cancer treatment developed alongside Johnson and Johnson. The United States Food and Drug Administration greenlit the medication, which contributed to the positive market movement for the biotech company.
Source: Read the full story at Stock Market News
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.